Insider Transactions in Q2 2021 at Natus Medical Inc (NTUS)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2021
|
Ilan Daskal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+27.33%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Alice D. Schroeder Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+23.13%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Lisa Wipperman Heine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+19.73%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Joshua Levine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+13.89%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Barbara R Paul Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+14.9%
|
$145,992
$28.77 P/Share
|
|
Jun 17
2021
|
Thomas Joseph Sullivan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,214
+20.46%
|
$145,992
$28.77 P/Share
|
|
Jun 11
2021
|
Ilan Daskal Director |
SELL
Open market or private sale
|
Direct |
2,500
-22.43%
|
$67,500
$27.46 P/Share
|
|
Jun 11
2021
|
Alice D. Schroeder Director |
SELL
Open market or private sale
|
Direct |
2,934
-19.49%
|
$79,218
$27.49 P/Share
|
|
Jun 01
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-23.84%
|
$337,500
$27.55 P/Share
|
|
May 28
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
808
-1.52%
|
$21,008
$26.9 P/Share
|
|
May 27
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,467
-16.43%
|
$282,609
$27.1 P/Share
|
|
May 25
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,435
-12.9%
|
$254,745
$27.41 P/Share
|
|
May 24
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-21.47%
|
$540,000
$27.11 P/Share
|
|
May 20
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,290
-9.07%
|
$250,830
$27.0 P/Share
|
|
May 19
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,367
-5.85%
|
$165,542
$26.54 P/Share
|
|
May 18
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,904
-2.6%
|
$75,504
$26.9 P/Share
|
|
May 14
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,927
-16.41%
|
$613,956
$28.31 P/Share
|
|
May 13
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,721
-17.18%
|
$748,467
$27.96 P/Share
|
|
May 12
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,108
-5.9%
|
$272,916
$27.47 P/Share
|
|
Apr 30
2021
|
Jonathan Kennedy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
489
+0.25%
|
$10,269
$21.72 P/Share
|
|
Apr 30
2021
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
489
+0.4%
|
$10,269
$21.72 P/Share
|